Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Makers LaboratoriesBOM:506919 -0.53%66 EBITDA Margin % is 16.88% as of Mar. 2026, which is 50% above its 10-year median of 11.26. GuruFocus rates BOM:506919 with a GF Score™ of 66/100 and a GF Value™ of ₹174.61 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 960 Drug Manufacturers companies, Makers Laboratories ranks worse than 51.88% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Makers Laboratories EBITDA Margin % Related Terms
Makers Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Makers Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Makers Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Makers Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Makers Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Makers Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Makers Laboratories (BOM:506919) has a EBITDA Margin % of 16.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Makers Laboratories and its competitors. This is 50% above median its historical median of 11.26. Over the past decade, Makers Laboratories' EBITDA Margin % has ranged from 2.49 to 16.90. According to the industry distribution chart, Makers Laboratories ranks #498 out of 960 companies in the Drug Manufacturers industry, placing it in the top 51.9%.
Is Makers Laboratories' EBITDA Margin % too high?
Makers Laboratories' current EBITDA Margin % of 16.88% is 50% above median its 10-year median of 11.26. Over the past 10 years, this metric has ranged from a low of 2.49 to a high of 16.90. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Makers Laboratories' value of 16.88% is 34.9% above this industry median. Based on the distribution chart, Makers Laboratories ranks #498 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Makers Laboratories has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Makers Laboratories' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Makers Laboratories ranks #498 out of 960 companies for EBITDA Margin %. This places Makers Laboratories in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Makers Laboratories' value of 16.88% is 34.9% above this benchmark. Historically, Makers Laboratories' own EBITDA Margin % has ranged from 2.49 to 16.90 over the past decade. While the company's 10-year median is 11.26 vs. the industry median of 12.52, Makers Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Makers Laboratories's current EBITDA Margin % of 16.88% is 34.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Makers Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Makers Laboratories's current EBITDA Margin % is 16.88%, which is 50% above median its own 10-year median of 11.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Makers Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Makers Laboratories (BOM:506919) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹174.61, compared to a current price of ₹151.50 — trading 13.2% below its estimated fair value. The current EBITDA Margin % is 16.88%, which is 50% above median its 10-year median of 11.26 and 34.9% above the Drug Manufacturers industry median of 12.52. Makers Laboratories' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Makers Laboratories (BOM:506919), the current EBITDA Margin % is 16.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Makers Laboratories (BOM:506919) Overvalued in 2026?
Based on GuruFocus' analysis, Makers Laboratories stock appears to be undervalued.
The current stock price of ₹151.50 is trading 13.2% below its estimated GF Value™ of ₹174.61.
GuruFocus considers Makers Laboratories to be Modestly Undervalued.
Key valuation signals for BOM:506919:
EBITDA Margin %: 16.88% (50% above median its 10-year median of 11.26)
GF Value™: ₹174.61 vs. price of ₹151.50 (13.2% below fair value)
Industry Position: 34.9% above the Drug Manufacturers median (#498 of 960)
No single metric tells the full story. See the BOM:506919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Makers Laboratories Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of pharmaceutical products. The company's product portfolio includes Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (Anti-Cough Range), and Exylin (Amoxycillin range), among others. The reportable segment of the company is the Pharmaceutical segment.
66GF Score
Get the complete analysis for BOM:506919
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506919 has been successfully added to your 
